The PwC Pharma and Life Sciences specialists are pleased to present you with the sixth issue of our Asia-Pacific pharmaceutical industry newsletter.
In this issue, we have two special reports for you. The first is on the Japanese health system and the initiatives to boost the use of generic drugs by medical institutes, pharmacies and government in order to reach national targets.
The second special report is focused on the Singaporean government’s investment in health information technology and their biomedical science research capabilities.
In our compliance section we have included highlights of the latest developments in the adherence to standards regarding the manufacturing of medicines and the potential threat of counterfeit products.
Find out more about the push for creating a more affordable market of pharmaceuticals for the masses in the Asia Pacific in our pricing section.
Read about the latest news from multiples in the territories in the tax section covering R&D credits, WHT, investment allowances, tax incentives, GST, thin capitalisation and transfer pricing developments.